PRNewswire

Second asset utilizing Adcentrx’s ADC platform to receive IND clearance Dosing of first patient in a Phase 1a/b clinical trial anticipated by 4Q 2024 SAN DIEGO, Oct. 21, 2024 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: